Adverum Biotechnologies, Inc. Stock price

Equities

ADVM

US00773U2078

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
14.14 USD -3.55% Intraday chart for Adverum Biotechnologies, Inc. -4.14% +87.83%
Sales 2024 * - Sales 2025 * 10M Capitalization 293M
Net income 2024 * -111M Net income 2025 * -143M EV / Sales 2024 * -
Net cash position 2024 * 149M Net cash position 2025 * 136M EV / Sales 2025 * 15.8 x
P/E ratio 2024 *
-2.62 x
P/E ratio 2025 *
-2.47 x
Employees 121
Yield 2024 *
-
Yield 2025 *
-
Free-Float 97.94%
More Fundamentals * Assessed data
Dynamic Chart
Adverum Biotechnologies Files $200 Million Mixed Shelf MT
RBC Cuts Price Target on Adverum Biotechnologies to $2 From $3, Keeps Sector Perform, Speculative Risk MT
Adverum Biotechnologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Adverum Biotechnologies, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Adverum Biotechnologies, Inc. announced that it has received $127.5 million in funding from a group of investors CI
Transcript : Adverum Biotechnologies, Inc. - Special Call
Adverum Biotechnologies, Inc. Announces Positive Preliminary Efficacy and Safety Data from Luna Phase 2 Trial of Ixo-Cov in Patients with Wet AMD CI
4D Molecular soars as mid-stage data for eye disease therapy 'checks all boxes' RE
Adverum Biotechnologies, Inc. announced that it expects to receive $127.5 million in funding from a group of investors CI
Adverum Biotechnologies, Inc. Appoints Romuald Corbau as Chief Scientific Officer and Member of Executive Committee CI
Adverum Biotechnologies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Adverum Biotechnologies, Inc. Appoints C. David Nicholson to the Board of Directors CI
Adverum Biotechnologies Announces Three-Year Efficacy and Safety Results from the OPTIC Extension Study in Patients with Wet AMD at AAO 2023 CI
Mizuho Starts Adverum Biotechnologies With Buy Rating, Price Target is $2 MT
Adverum Biotechnologies, Inc. Announces Positive Aflibercept Protein Level Data from the Luna Phase 2 Trial CI
More news

Latest transcript on Adverum Biotechnologies, Inc.

1 day-3.55%
1 week-4.14%
Current month-28.59%
1 month-28.22%
3 months+87.04%
6 months-7.58%
Current year+87.83%
More quotes
1 week
13.67
Extreme 13.67
16.44
1 month
13.67
Extreme 13.67
20.90
Current year
7.53
Extreme 7.531
29.70
1 year
6.81
Extreme 6.81
29.70
3 years
5.31
Extreme 5.31
108.50
5 years
5.31
Extreme 5.31
269.80
10 years
5.31
Extreme 5.31
624.80
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 20-06-14
Director of Finance/CFO 58 22-12-11
Chief Tech/Sci/R&D Officer - 21-02-28
Members of the board TitleAgeSince
Director/Board Member 64 20-04-15
Chairman 60 17-03-13
Chief Executive Officer 60 20-06-14
More insiders
Date Price Change Volume
24-03-28 14.14 -3.55% 109,879
24-03-27 14.66 +3.60% 166,895
24-03-26 14.15 -5.35% 682,661
24-03-25 14.95 -6.91% 357,284
24-03-22 16.06 +8.88% 576,559

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company. The Company discovers and develops gene therapy product candidates that provides durable efficacy by inducing sustained expression of a therapeutic protein. Its lead product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable levels of aflibercept associated with a sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) IVT injections. Ixo-vec is being developed for the treatment of patients with wet age-related macular degeneration. Its second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a gene therapy product candidate being developed to treat patients suffering from blue cone monochromacy (BCM) via a single IVT injection. It also developing an early-stage pipeline of gene therapy programs.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
14.14 USD
Average target price
40 USD
Spread / Average Target
+182.89%
Consensus
  1. Stock
  2. Equities
  3. Stock Adverum Biotechnologies, Inc. - Nasdaq